# **Product** Data Sheet

## **NU6300**

Target:

Cat. No.: HY-18930 CAS No.: 2070015-09-5 Molecular Formula:  $C_{20}H_{23}N_5O_3S$ Molecular Weight: 413.49

Pathway: Cell Cycle/DNA Damage

Storage: Powder -20°C 3 years

CDK

2 years

-80°C In solvent 2 years

> -20°C 1 year

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO : ≥ 32 mg/mL (77.39 mM)

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.4184 mL	12.0922 mL	24.1844 mL
	5 mM	0.4837 mL	2.4184 mL	4.8369 mL
	10 mM	0.2418 mL	1.2092 mL	2.4184 mL

Please refer to the solubility information to select the appropriate solvent.

## **BIOLOGICAL ACTIVITY**

IC<sub>50</sub> & Target

Description  $NU6300\ is\ a\ covalent,\ irreversible\ and\ ATP-competitive\ CDK2\ inhibitor\ with\ an\ IC_{50}\ value\ of\ 0.16\ \mu M.\ NU6300\ can\ be\ used\ for\ nU63000\ can\ be\ u$ the research of eukaryotic cell cycle- and transcription-related<sup>[1]</sup>.

CDK2

NU6300 (50  $\mu\text{M};$  0-1 hour) covalently modifies and irreversible inhibits CDK2  $^{[1]}.$ In Vitro

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis<sup>[1]</sup>

Cell Line:	SKUT-1B cells
Concentration:	50 μΜ
Incubation Time:	0-1 hour

Resu	lt:	Affected retinoblastoma tumor suppressor protein (Rb) phosphorylation in SKUT-1B cells		
		and covalently binded with CDK2.		

#### **REFERENCES**

[1]. Anscombe E, et al. Identification and Characterization of an Irreversible Inhibitor of CDK2. Chem Biol. 2015 Sep 17;22(9):1159-1164.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com